Press release
Overactive Bladder Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape
Stay ahead with the latest insights! Download DelveInsight's comprehensive Overactive Bladder Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Overactive Bladder Pipeline Outlook Report [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Overactive Bladder Pipeline Report
* In January 2025, Imbrium Therapeutics L.P . ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase Ib clinical signal detection study evaluating the safety and efficacy of the novel investigational treatmentsunobinop in patients with overactive bladder syndrome.
* DelveInsight's Overactive Bladder pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Overactive Bladder treatment.
* The leading Overactive Bladder Companies such as Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
* Promising Overactive Bladder Pipeline Therapies such as GSK1358820, YM178, Fesoterodine 8 mg, Vibegron, Tolterodine ER, Solifenacin Succinate, Oxybutynin chloride OROS, VESIcare Registered , Fesoterodine , and others.
Discover how the Overactive Bladder treatment paradigm is evolving. Access DelveInsight's in-depth Overactive Bladder Pipeline Analysis for a closer look at promising breakthroughs @ Overactive Bladder Clinical Trials and Studies [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Overactive Bladder Emerging Drugs Profile
* Neuronox: AbbVie/Medytox
Neuronox, an acetylcholine inhibitor is being developed by Medy-Tox for the treatment of the Overactive Bladder. The active ingredients involve Clostridium botulinum toxin type A. It is currently in the phase III stage of development. In September 2020, US drugmaker Allergan entered into a license agreement with South Korea's Medytox under the terms of which, on closing, Allergan would pay Medytox an upfront of USD 65 million and Medytox would grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialise certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. In May 2020, AbbVie announced that it had finished its acquisition of Allergan plc following receipt of regulatory approval from all government authorities needed by the transaction agreement and approval by the Irish High Court.
* URO-902: Urovant Sciences
Urovant Sciences is developing URO-902 for the treatment of the Overactive Bladder. URO-902 has the potential to be the first gene therapy for OAB patients. This innovative treatment has the capability to tackle an unmet need for patients who have failed oral pharmacologic therapies and are concerned with potential urinary retention or surgical interventions pertinent to existing third-line OAB treatments. It is currently in the phase II stage of development.
The Overactive Bladder Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
* Overactive Bladder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
Get a detailed analysis of the latest innovations in the Overactive Bladder pipeline. Explore DelveInsight's expert-driven report today! @ Overactive Bladder Unmet Needs [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Overactive Bladder Companies
Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
Overactive Bladder Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Overactive Bladder Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Overactive Bladder Therapies and key Developments @ Overactive Bladder Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Overactive Bladder Pipeline Report
* Coverage- Global
* Overactive Bladder Companies- Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
* Overactive Bladder Pipeline Therapies- GSK1358820, YM178, Fesoterodine 8 mg, Vibegron, Tolterodine ER, Solifenacin Succinate, Oxybutynin chloride OROS, VESIcare Registered , Fesoterodine , and others.
* Overactive Bladder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Overactive Bladder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Overactive Bladder drug development? Find out in DelveInsight's exclusive pipeline report-access it now! @ Overactive Bladder Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/overactive-bladder-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Overactive Bladder: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Overactive Bladder- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Neuronox: AbbVie/Medytox
* Mid Stage Products (Phase II)
* URO-902: Sumitovant Biopharma
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Overactive Bladder Key Companies
* Overactive Bladder Key Products
* Overactive Bladder- Unmet Needs
* Overactive Bladder- Market Drivers and Barriers
* Overactive Bladder- Future Perspectives and Conclusion
* Overactive Bladder Analyst Views
* Overactive Bladder Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=overactive-bladder-pipeline-outlook-report-2025-key-15-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Overactive Bladder Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4137651 • Views: …
More Releases from ABNewswire
Language Learn Online is proud to be offering Dutch Lessons to the Amsterdam
Amsterdam Dutch Lessons & Courses | Language Learn Online announces the launch of expanded Dutch lessons programs designed for internationals living, working, or studying in Amsterdam. The new offerings include flexible in-person lessons throughout Amsterdam and convenient online courses for remote learners. Amsterdam Dutch Lessons & Courses | Language Learn Online [https://languagelearnonline.com/dutch-lessons-classes/amsterdam] provides tailored Dutch lessons for expats, international students, and professionals seeking to improve communication skills, integrate into Dutch…
Vascular Closure Devices Market Projected for Steady Growth Through 2032, Fueled …
Global vascular closure devices market is expected to increase from USD 1,548.87 million in 2024 to USD 2,398.52 million by 2032, reflecting strong and sustained growth, estimates DelveInsight.
The global vascular closure devices market was valued at USD 1.05 billion in 2023 and is expected to expand at a CAGR of 6.15%, reaching around USD 1.49 billion by 2030. Market growth is primarily driven by the increasing prevalence of chronic conditions,…
Non-Invasive Prenatal Testing Market Poised for Consistent Growth Through 2032, …
The Down's Syndrome Association stated that around one in every 1000 babies born in the United Kingdom has Down's syndrome. in 2023, there were approximately 47,000 people in the UK with the condition.
The global non-invasive prenatal testing (NIPT) market, valued at USD 3,916 million in 2023, is projected to expand at a compound annual growth rate (CAGR) of 9.22%, reaching around USD 6,645 million by 2030. This growth is primarily…
Fanconi anemia Pipeline 2025: Significant Clinical Developments by 3+ Global Lea …
DelveInsight's, "Fanconi Anemia (FA) - Pipeline Insight, 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Fanconi Anemia (FA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Fanconi anemia continues to impact populations worldwide…
More Releases for Overactive
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Emerging Trends Influencing The Growth Of The Overactive Bladder Treatment Marke …
The Overactive Bladder Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Overactive Bladder Treatment Market?
The market size for overactive bladder treatments has been consistently expanding over the past few years. The market is projected to increase from…
Top Factor Driving Overactive Bladder Treatment Market Growth in 2025: Geriatric …
What industry-specific factors are fueling the growth of the overactive bladder treatment market?
The anticipated growth of the overactive bladder treatment market is largely attributed to an increasing geriatric population. This term pertains to individuals who are 65 years old and above. The susceptibility of geriatric patients to urinary tract infections is higher due to multiple factors like reduced urine flow, overactive bladder, enlarged prostate or presence of kidney stones, thereby…
Overactive Bladder Market - Empowering Life Without Limits: Overactive Bladder S …
Newark, New Castle, USA - new report, titled Overactive Bladder Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Overactive Bladder market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Overactive Bladder market. The report offers an overview of the market, which…
Overactive Bladder Market Report, History and Forecast 2022-2030
Overactive Bladder Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Overactive Bladder industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview…
Overactive Bladder Treatment Market by Drug Type (Anticholinergics, Mirabegron, …
Market Analysis and Insights of Overactive Bladder Treatment Market
During the forecasted period of 2023-2032, the market for treatments for overactive bladder will grow at a CAGR of about 4.00%. The main drivers of the overactive bladder treatment market's expansion are the rising prevalence of kidney-related disorders, increased emphasis on medical device research and development expertise and the adoption of cutting-edge IT healthcare technologies, an increasing geriatric population worldwide, and rising…
